secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2026-08-28T21:08:50+00:00
Accession:  0001087294-26-000064
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland delays release of FIGHT DMD ifetroban long-term data; no new timeline
--------------------------------------------------------------------------------

- Phase 2 FIGHT DMD open-label extension long-term safety/efficacy data for ifetroban not yet available.
- Company no longer expects to present data in August 2026 as stated at PPMD conference on June 26, 2026.
- Data was originally expected at Parent Project Muscular Dystrophy annual conference in Orlando.
- Cumberland will present at a future date when data becomes available; no revised timeline given.
- Ifetroban is an oral candidate for Duchenne muscular dystrophy heart disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000064/0001087294-26-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000108729426000064/cpix-20260828.htm
  HTML page:      https://secwatch.observer/filing/0001087294-26-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer